hims & hers SUPPLEMENTAL PRESENTATION Investor Presentation August 2025 > INTRODUCTION Safe Harbor Statement This presentation has been prepared by Hims & Hers Health, Inc. ("we," "us," "us," "Hims & Hers," or the "Company"). This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and performance to be materially different from those expressed or implied by these forward-looking statements. These risks and Section 21E of the Securitie ...

Core Insights - Hims & Hers Health reported a 73% increase in revenue for the second quarter, reaching $544.8 million compared to $315.6 million in the same period last year [1] - The company experienced a net income of $42.5 million, or 17 cents per share, up from $13.3 million, or 6 cents per share, year-over-year [1] - Despite strong year-over-year growth, the company's second-quarter results fell short of Wall Street's revenue expectations, leading to a 9% decline in shares during extended trading [1] Revenue Expectations - For the third quarter, Hims & Hers anticipates revenue between $570 million to $590 million, slightly below analysts' expectations of $583 million [2] - The adjusted EBITDA for the upcoming quarter is projected to be between $60 million to $70 million, while analysts had expected $77.1 million [2] Earnings Comparison - The adjusted earnings per share for the second quarter were reported at 17 cents, compared to an expectation of 15 cents [3] - Revenue for the second quarter was reported at $544.8 million, which was slightly below the expected $552 million [3]

Financial Performance - Revenue for Q2 2025 reached $544.8 million, a 73% increase from $315.6 million in Q2 2024[20] - Gross profit for Q2 2025 was $416.2 million, compared to $256.6 million in Q2 2024, reflecting a 62% increase[20] - Net income for the first half of 2025 was $92.0 million, significantly up from $24.4 million in the same period of 2024[20] - Total revenue for the six months ended June 30, 2025, reached $1.13 billion, compared to $593.82 million for the same period in 2024, reflecting a 90% year-over-year growth[52] - Segment net income for the three months ended June 30, 2025, was $42.505 million, up from $13.297 million in the same period of 2024, indicating a significant growth in profitability[152] - Net income for Q2 2025 was $42.5 million, a significant increase of 220% from $13.3 million in Q2 2024[203] Assets and Liabilities - Total current assets increased to $1.36 billion as of June 30, 2025, compared to $395.8 million at the end of 2024[18] - Total assets reached $1.88 billion as of June 30, 2025, up from $707.5 million at the end of 2024[18] - Total liabilities increased to $1.31 billion as of June 30, 2025, compared to $230.8 million at the end of 2024[18] - Stockholders' equity rose to $562.7 million as of June 30, 2025, up from $476.7 million at the end of 2024[18] Cash Flow and Investments - Cash and cash equivalents increased to $1.12 billion as of June 30, 2025, compared to $220.6 million at the end of 2024[18] - Net cash provided by operating activities increased to $89,973 for the six months ended June 30, 2025, up from $79,432 in 2024, reflecting a growth of 13.5%[29] - The company incurred $101,392 in purchases of property, equipment, and intangible assets during the six months ended June 30, 2025, compared to $13,793 in 2024, reflecting a significant increase of 634%[29] - The company recognized cash paid for taxes of $23,047 for the six months ended June 30, 2025, compared to $3,468 in 2024, representing a substantial increase of 563%[29] - The company’s total cash flow from investing activities was negative at $(53,884) for the six months ended June 30, 2025, compared to a positive cash flow of $8,572 in 2024, indicating a significant shift in investment cash flow[29] Revenue Streams - Online Revenue for the three months ended June 30, 2025, was $536.88 million, a 75% increase from $306.84 million in the same period of 2024[52] - The Company's GLP-1 offerings generated approximately $190 million and $420 million in Online Revenue for the three and six months ended June 30, 2025, respectively[171] - Wholesale Revenue for the three months ended June 30, 2025, was $8.0 million, a decrease of $0.9 million, or 10%, compared to $8.8 million for the same period in 2024[173] Expenses - Operating expenses for Q2 2025 were $389.5 million, up from $245.6 million in Q2 2024, representing a 58% increase[20] - Marketing expenses for Q2 2025 were $217.9 million, a 50% increase from $144.9 million in Q2 2024[203] - Technology and development expenses for Q2 2025 were $37.8 million, a 103% increase from $18.7 million in Q2 2024[203] - General and administrative expenses for Q2 2025 were $67.3 million, a 66% increase from $40.6 million in Q2 2024[203] Acquisitions - The Company acquired C S Bio Co. for up to $39.1 million to enhance supply chain capabilities, with an upfront payment of approximately $32.7 million[63] - The acquisition of Sigmund NJ, LLC (Trybe Labs) was completed for $5.1 million, adding lab testing capabilities to the platform[66] - The Company acquired Zava Global GmbH for up to approximately EUR 225.0 million ($265.7 million), aiming to expand its footprint in the UK and enter European markets[158] Stock and Equity - The 2024 Share Repurchase Program allows for the repurchase of up to $100.0 million of Class A common stock, with $65.0 million remaining available as of June 30, 2025[119] - For the six months ended June 30, 2025, the company released 3,783,712 gross shares of Class A common stock upon vesting of RSUs, with 1,420,506 shares withheld for employee taxes[120] - As of June 30, 2025, there were 65,403,042 shares of Class A common stock reserved and 22,285,450 shares available for grant under the 2020 Equity Incentive Plan[122] Future Outlook - The Company anticipates that personalized offerings will increasingly drive Online Revenue growth in the future[171] - The company expects to continue investing in fulfillment, distribution, and operating capabilities, including its recently acquired facilities, over the next 12 months[179] - The company anticipates that the resolution of the semaglutide shortage will impact Subscriber retention and revenue in the near term[178]

Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Af irms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million SAN FRANCISCO, August 4, 2025 – Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), t ...

Core Viewpoint - Novo Nordisk terminated its collaboration with Hims & Hers due to concerns over sales practices and "deceptive" marketing of the weight-loss drug Wegovy® [1][5]. Group 1: Company Actions and Legal Implications - Novo Nordisk's termination of the partnership with Hims & Hers occurred less than two months after the collaboration began, highlighting serious regulatory compliance issues [5]. - Following Novo Nordisk's announcement, securities class action lawsuits were filed against Hims & Hers and its executives, representing investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [2][6]. - Legal claims allege that Hims & Hers misled investors regarding its regulatory compliance and the revenue potential from its GLP-1 drug offerings [6][7]. Group 2: Regulatory Concerns and Market Impact - A group of over 80 bipartisan lawmakers urged the FDA to address the rising market for counterfeit GLP-1 drugs, citing risks to patient safety [4]. - The lawmakers' concerns were amplified by the fallout from the Hims & Hers and Novo Nordisk collaboration, which was marred by allegations of illegal compounding and deceptive marketing practices [4][5]. - Hims & Hers is accused of promoting unauthorized versions of Wegovy®, which could jeopardize patient safety and the company's relationship with Novo Nordisk [7][8].

NEW YORK, Aug. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=159218&from=4 SOURCE The Gross Law ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, titled Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, for seeking lead plaintiff status [1][4]. - The lawsuit alleges that Hims & Hers made false statements and failed to disclose risks associated with its collaboration with Novo Nordisk, particularly regarding the safety of its products [2][3]. - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing deceptive practices that jeopardized patient safety, leading to a stock price decline of over 34% [3]. Group 2: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Hims & Hers securities during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [4]. - The lead plaintiff can choose a law firm to represent the class, and participation as lead plaintiff does not affect the ability to share in any potential recovery [4]. Group 3: Company Background - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, is recognized as a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and illegal practices that have led to significant investor losses [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 22, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Hims engaged in deceptive practices, including the promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety [4]. Group 2: Partnership Termination and Stock Impact - Novo Nordisk announced the termination of its partnership with Hims on June 23, 2025, citing Hims' failure to comply with legal standards regarding drug sales [5]. - Following the announcement, Hims' stock price plummeted by $22.24, or 34.6%, closing at $41.98 per share, resulting in significant financial harm to investors [5]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct [7].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, particularly related to misrepresentation of a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and asserted compliance with FDA regulations [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share [5].

RADNOR, Pa., Aug. 02, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is Augus ...